Ignite Creation Date:
2024-05-06 @ 7:24 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT05999812
Status:
RECRUITING
Last Update Posted:
2024-01-19
First Post:
2023-08-11
Brief Title:
Clinical Trial of All-trans-retinoic Acid Bevacizumab and Atezolizumab in Colorectal Cancer
Sponsor:
University of Texas Southwestern Medical Center
Organization:
University of Texas Southwestern Medical Center
Study Overview
Official Title:
Phase II Single-arm Single-center Clinical Trial of All-trans-retinoic Acid Bevacizumab and Atezolizumab in Refractory Microsatellite Stable Colorectal Cancer
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this clinical trial is to learn about the good and the bad effects of all trans retinoic acid ATRA atezolizumab and bevacizumab as a possible treatment for advanced colorectal patients
Participants will be treated with the following combination of these drugs
1 ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on day 1 of a cycle
2 Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW
3 Bevacizumab will be given through a vein in arm or through mediport over 20-40 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW
Participants will be treated with the following combination of these drugs
1 ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on day 1 of a cycle
2 Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW
3 Bevacizumab will be given through a vein in arm or through mediport over 20-40 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None